Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
- 1 April 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 22 (4), 391-398
- https://doi.org/10.1097/meg.0b013e328333df23
Abstract
An expert panel was convened to reach a consensus on the current use of sorafenib in the treatment of hepatocellular carcinoma (HCC). A multinational, multidisciplinary group of experts objectively reviewed clinical data of sorafenib and considered clinical experience to develop statements summarizing our consensus on the current use of sorafenib. Sorafenib is the standard of care for Child–Pugh (CP) A patients with advanced HCC (i.e. not amenable to surgery or locoregional treatment). There is currently insufficient evidence to support the routine clinical use of sorafenib in CP B patients, but sorafenib can be offered as an option for those with compensated liver cirrhosis. Patients with stable performance status who have progressive disease during sorafenib treatment can be maintained on sorafenib, although there are no clear data supporting the continuation of sorafenib in these patients. The effectiveness of the adjuvant use of sorafenib in preventing recurrence after resection or local ablation, or in combination with transarterial chemoembolization, are being evaluated in clinical studies. In conclusion, sorafenib has extended treatment options for patients with HCC, and is now established as the standard of care for CP A patients with HCC not amenable to surgery or locoregional treatment. Based on its multikinase-inhibitor activity and proven efficacy in prolonging survival in HCC, broader use – including a subgroup of patients with CP B (clinically compensated cirrhosis) and earlier disease stages – might be expected dependent on the results of ongoing studies of safety and clinically relevant benefit in these patients.Keywords
This publication has 36 references indexed in Scilit:
- Commentary: Sorafenib Use in Patients with Advanced Hepatocellular Carcinoma and Underlying Child-Pugh B Cirrhosis—Evidence and ControversyThe Oncologist, 2009
- Treatment and prognosis of hepatocellular carcinoma: A population based study in FranceJournal of Surgical Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals Of Oncology, 2007
- Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trialsAlimentary Pharmacology & Therapeutics, 2006
- Primary liver cancer: Worldwide incidence and trendsGastroenterology, 2004
- The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An UpdateAnnals of Internal Medicine, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002